First-trimester contingent screening for down syndrome can reduce the number of nuchal translucency measurements required

Prenatal Diagnosis

Volumn 29, Issue 1, 2009, Pages 79-82

  Vadiveloo, Thenmalar ^a   Crossley, Jennifer A ^a   Aitken, David A ^a  

^a Medical Genetics   (United Kingdom)

Author keywords

Down syndrome; First trimester; Nuchal translucency; Prenatal screening; Serum markers

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

CLINICAL PROTOCOL; CONFERENCE PAPER; CONTINGENT VALUATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DOWN SYNDROME; FALSE POSITIVE RESULT; FIRST TRIMESTER PREGNANCY; GENETIC SCREENING; HIGH RISK PREGNANCY; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST;

ADULT; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; COHORT STUDIES; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; SENSITIVITY AND SPECIFICITY;

EID: 59449087586     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2185     Document Type: Conference Paper

References (10)

1. Christiansen M, Larsen S. 2002. An increase in cost-effectiveness of first trimester maternal screening programmes for fetal chromosome anomalies is obtained by contingent testing. Prenat Diagn 22(6): 482-486.
2. Christiansen M, Nørgaard-Pedersen B. 2005. Inhibin A is a maternal serum marker for Down's syndrome early in the first trimester. Clin Genet 68(1): 35-39.
3. Cuckle H. 2000. Biochemical screening for Down syndrome. Eur J Obstet Gynecol Reprod Biol 92: 97-101.
4. Laigaard J, Spencer K, Christiansen M, et al. 2006. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome. Prenat Diagn 26(10): 973-979.
5. Spencer K, Crossley J, Aitken D, Nix A, Dunstan F, Williams K. 2002. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 39(Pt 6): 567-576.
6. Spencer K, Crossley J, Aitken D, Nix A, Dunstan F, Williams K. 2003. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome. Ann Clin Biochem 40(Pt 3): 219-231.
7. Spencer K, Spencer C, Power M, Moakes A, Nicolaides K. 2000. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG 107(10): 1271-1275.
8. Stenhouse E, Crossley J, Aitken D, Brogan K, Cameron A, Connor J. 2004. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice. Prenat Diagn 24(10): 774-780.
9. Stenhouse EJ, Crossley JA, Eddowes H, Aitken DA, Cameron AD. 2002. The quality control of nuchal translucency measurement during routine first trimester screening for Down's Syndrome. J Obstet Gynaecol 22(Suppl. 1): S39.
10. Wald N, Watt H, Hackshaw A. 1999. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 341(7): 461-467.